Our paper reported that FLT3-ITD-positive AML cells are addicted to HSP90 activity, and that the HSP90 family member GRP94 is required for aberrant endoplasmic reticulum retention of FLT3-ITD. We have reason to question the provenance of the data shown in Figures 2E, 2F, 2G, 2H, 4A, 4C, 5D, 5E, S2A, S2D, S2E, S3B, S3F, S4E, S4F and S4I, as well as the zebrafish images shown in Figure 7, all of which were prepared by the first author of the article. The figures provided by all other authors are not in question. While we believe the overall conclusions of our manuscript remain intact, the most appropriate course of action is to retract the paper. All authors have agreed to this Retraction. We deeply regret this circumstance and apologize to the scientific community for the inconvenience that this may have caused.
letter . 2019 May;104(5):e229. doi: 10.3324/haematol.2019.220533
GRP94 rewires and buffers the FLT3-ITD signaling network and promotes survival of acute myeloid leukemic stem cells
Beibei Zhang
1,2,3, Pilar Ayuda-Durán
1,2,3, Laure Piechaczyk
1,2,4, Yngvar Fløisand
1,2,5, Mireia Mayoral Safont
6, Ida Tveit Karlsen
6, Zina Fandalyuk
6, Dagim Tadele
1,2,4, Pepijn van Mierlo
1, Alexander D Rowe
7, Joseph M Robertson
1,2, Bjørn Tore Gjertsen
5,8, Emmet McCormack
5,8, Jorrit M Enserink
1,2,9,✉
Beibei Zhang
1Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Montebello
2Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, Montebello
Find articles by Beibei Zhang
Pilar Ayuda-Durán
1Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Montebello
2Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, Montebello
Find articles by Pilar Ayuda-Durán
Laure Piechaczyk
1Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Montebello
2Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, Montebello
4Institute of Clinical Medicine, University of Oslo
Find articles by Laure Piechaczyk
Yngvar Fløisand
1Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Montebello
2Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, Montebello
5Department of Hematology, Oslo University Hospital, Rikshospitalet, Oslo
Find articles by Yngvar Fløisand
Mireia Mayoral Safont
6Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen
Find articles by Mireia Mayoral Safont
Ida Tveit Karlsen
6Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen
Find articles by Ida Tveit Karlsen
Zina Fandalyuk
6Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen
Find articles by Zina Fandalyuk
Dagim Tadele
1Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Montebello
2Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, Montebello
4Institute of Clinical Medicine, University of Oslo
Find articles by Dagim Tadele
Pepijn van Mierlo
1Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Montebello
Find articles by Pepijn van Mierlo
Alexander D Rowe
7Norwegian National Unit for Newborn Screening, Woman and Children’s Division, Oslo University Hospital, Rikshospitalet
Find articles by Alexander D Rowe
Joseph M Robertson
1Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Montebello
2Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, Montebello
Find articles by Joseph M Robertson
Bjørn Tore Gjertsen
5Department of Hematology, Oslo University Hospital, Rikshospitalet, Oslo
8Hematology Section, Department of Internal Medicine, Haukeland University Hospital, Bergen
Find articles by Bjørn Tore Gjertsen
Emmet McCormack
5Department of Hematology, Oslo University Hospital, Rikshospitalet, Oslo
8Hematology Section, Department of Internal Medicine, Haukeland University Hospital, Bergen
Find articles by Emmet McCormack
Jorrit M Enserink
1Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Montebello
2Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, Montebello
9Section for Biochemistry and Molecular Biology, The Department of Biosciences, Faculty of Mathematics and Natural Sciences, University of Oslo, Norway
Find articles by Jorrit M Enserink
1Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Montebello
2Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, Montebello
4Institute of Clinical Medicine, University of Oslo
5Department of Hematology, Oslo University Hospital, Rikshospitalet, Oslo
6Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen
7Norwegian National Unit for Newborn Screening, Woman and Children’s Division, Oslo University Hospital, Rikshospitalet
8Hematology Section, Department of Internal Medicine, Haukeland University Hospital, Bergen
9Section for Biochemistry and Molecular Biology, The Department of Biosciences, Faculty of Mathematics and Natural Sciences, University of Oslo, Norway
✉
To whom correspondence should be addressed: jorrit.enserink@rr-research.no
3
Equal contributions
Copyright© 2019 Ferrata Storti Foundation
PMCID: PMC6518908 PMID: 31040234